By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Up Close and Very Personal with Your Brain
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Up Close and Very Personal with Your Brain
DiagnosticsMedical InnovationsNewsRadiologySpecialtiesTechnology

Up Close and Very Personal with Your Brain

Steve Goldstein
Steve Goldstein
Share
4 Min Read
SHARE

Dementia is a growing problem and a huge burden on the health care system. Approximately 14 percent suffer worldwide and the prevalence among those 80 years of age and older is 24 percent. Alzheimer’s disease is now the sixth leading cause of death in the United States, with some estimates suggesting one person develops Alzheimer’s every 68 seconds. Deaths from this disease have increased 66 percent between 2000 and 2008 and there are now an estimated 5.4 million cases of Alzheimer’s domestically and 35 million worldwide.

Dementia is a growing problem and a huge burden on the health care system. Approximately 14 percent suffer worldwide and the prevalence among those 80 years of age and older is 24 percent. Alzheimer’s disease is now the sixth leading cause of death in the United States, with some estimates suggesting one person develops Alzheimer’s every 68 seconds. Deaths from this disease have increased 66 percent between 2000 and 2008 and there are now an estimated 5.4 million cases of Alzheimer’s domestically and 35 million worldwide.

Typically, Alzheimer’s has been difficult to diagnose, with certainty often not available until autopsy. So when new imaging technologies appear that may help detect Alzheimer’s, notice is taken. At the SNM annual meeting in Miami, Siemens Healthcare is demonstrating and extolling its integrated amyloid imaging solution, a combination of hardware and software as well as a reliable imaging biomarker. Amyloids are proteins that create plaque in the brain, inhibiting neurons, in much the same way that arterial plaque causes heart disease.

The first element of the solution is the Biograph mCT positron emission tomography/computer tomography (PET-CT) system. What’s interesting about this machine is that it can reportedly differentiate between gray and white brain matter with higher resolution that can not only visualize the uptake of amyloids but quantify the uptake.

More Read

photo of hands with blue veins
8 Proven Tips on Finding Difficult Veins
How to Obtain Mugshots Online for a Medical Liability Lawsuit
Google Fitness Platform And The Future Of Fitness Apps
Melbourne’s Music Scene: A Symphony for Your Senses
POLL RESULTS: What is the single greatest health benefit afforded by Digital Health solutions?

Alexander R. Zimmermann, Siemen’s vice president of marketing and sales for molecular imaging, said that the Biograph is a key part of a puzzle they’ve been working on for nearly six years.

“We’re very happy to introduce the world’s first integrated solution for amyloid imaging, which consists of the availability, manufacturing and distribution of a new imaging biomarker for amyloid uptake in the brain, a scanner that is made to visualize this marker with a higher volumetric resolution and a probability of quantification, and an FDA-pending software that will offer a ratio analysis,” he said in an interview. “We believe this is revolutionary because it’s offering for the first time a PET visualization of amyloids and therefore supports early insights into the diagnosis of Alzheimer’s.”

Nine U.S. medical facilities already have the Biograph, with another 16 slated to have installations by year’s end.

Siemen’s was mum about the biomarker component of the integrated solution because it is being developed and shepherded by Eli Lilly and Company under the trade name Amyvid. Lilly is close-holding the information, but we’ve asked for comment.

 

 

 

 

 

TAGGED:Alzheimer's Diseasebiograph
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

Dealing with DLP and privacy

August 16, 2015

Exponential Learning at Exponential Medicine

November 14, 2014
consumer-driven-digital-disruption.png
BusinesseHealthMedical InnovationsMobile HealthTechnology

The Consumer-Driven, Digital Disruption in Healthcare

April 4, 2016
BusinessTechnology

Digital Wayfinding: How SEO Impacts Patient Outcomes

December 13, 2017
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?